INCY at LOw of the Day - this is getting frustrating. What gives?
someone is buying cheap before
In 2013, Incyte will start receiving royalties on ex-U.S. sales from its partner Novartis.
Baricitinib is Incyte's most advanced development-stage program, partnered with Lilly (LLY). The drug is in a broad phase III campaign, focusing on RA, where phase II results demonstrated similar efficacy to that of Pfizer's recently approved Jak inhibitor (Xeljanz). Originally, Baricitinib was expected to be launched in a market with 2 established oral drugs (Pfizer's Xeljanz and AstraZeneca/Rigel's (RIGL) fostamatinib. Recent disappointing phase II data for fostamatinib imply it is not as effective as hoped and should be viewed as an incrementally positive development for Incyte.